National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Nivolumab (Opdivo®) as monotherapy for the adjuvant treatment of adults with melanoma  with involvement of lymph nodes or metastatic disease who have undergone complete resection.

NCPE Assessment Process Complete
Rapid review commissioned 09/07/2018
Rapid review completed 27/07/2018
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of nivolumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 01/08/2018
Pre-submission consultation with Applicant 03/09/2018
Submission received from Applicant 30/11/2018
Preliminary review sent to Applicant 26/03/2019
NCPE assessment re-commenced 25/04/2019
Current Status HTA assessment ongoing